hypertension), and the value of the PRS over and above these factors remain unclear. Evaluating the capability of the trans-ancestry PRS in identifying incident cases (i.e., individuals at risk to develop the disease in a future time window) in prospective cohorts and combining common-variant PRS with other genetic and non-genetic risk factors and family history into an integrated risk estimate would better define the clinical impact of the PRS.
